Clinical trials: Differentiated Thyroid Carcinoma
Differentiated Thyroid Cancer, Lymph Node Metastases
Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
Background: Despite a favorable prognosis, metastatic cervical lymph nodes (LN), are not uncommon among patients with differentiated thyroid cancer (DTC).
- Trial name
- NCT05078853
- Testing
- Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node
- Where
- 5 sites in Israel
- Volunteers
- 250 people
- Sponsor
- Soroka University Medical Center
Thyroid Carcinoma
Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
Correlation analysis between estimated renal function and biological half life of 131-I during radioiodine treatment of patients with differentiated thyroid cancer.
- Trial name
- RETENTION (NCT02773667)
- Where
- Germany
- Volunteers
- 83 people
- Sponsor
- Jena University Hospital
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
This study aims to observe and explore the efficacy and safety of Anlotinib combined with penpulimab in the treatment of radioiodine refractory differentiated thyroid cancer with first-line resistance to angiogenesis inhibitors…
- Trial name
- NCT06062563
- Testing
- Anlotinib Hydrochloride Capsule and Penpulimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking Union Medical College Hospital
Thyroid Neoplasms
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine
- Trial name
- NCT00984282
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 81 sites in United States, Austria and 16 more
- Volunteers
- 417 people
- Sponsor
- Bayer
Thyroid Cancer, Recurrence
Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma
Several studies have indicated that [124I]-PET/CT or [18F]-FDG-PET/CT may be useful to locate recurrent differentiated thyroid carcinoma lesions in patients with elevated thyroglobulin levels but who do not show pathological…
- Trial name
- NCT01374659
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Korean Association of Endocrine Surgeons
Thyroid Cancer
Outcome of RAI131 Therapy in Patients With Differentiated Thyroid Cancer (Low and Intermediate Risk)
Thyroid cancer is a universally relatively rare neoplasm, accounting for nearly 1-5% of all female cancers and less than 2% of male cancers.
- Trial name
- NCT07056218
- Testing
- neck ultrasound, thyroglobulin
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sohag University
Differentiated Thyroid Cancer
Pembrolizumab in High-risk Thyroid Cancer
This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance.
- Trial name
- NePenThe (NCT05852223)
- Testing
- Pembrolizumab
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Thyroid Cancer
Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer
The treatment of differentiated thyroid cancer (DCT) includes surgery followed by radioiodine treatment. In the follow-up of patients it is necessary to induce TSH elevation to test for cancer recurrence.
- Trial name
- NCT01840332
- Testing
- L-thyroxin
- Where
- 2 sites in Estonia
- Volunteers
- 20 people
- Sponsor
- University of Tartu
Thyroid Neoplasms
Assessment of Quality of Life After Adjunct Radioiodine Therapy in Patients With Differentiated Thyroid Cancer
The aim of this study was to assess the impact of adjuvant radioactive iodine therapy on the quality of life(QOL) in differentiated thyroid cancer patients and to identify independent factors affecting changes in the QOL.
- Trial name
- NCT02706743
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Southern Medical University, China
Thyroid Neoplasms
Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.
- Trial name
- NCT00279721
- Testing
- IMRT
- Volunteers
- 40 people
- Sponsor
- Alberta Health services
Pathologically Confirmed Differentiated Thyroid Carcinoma, All Patients Are in the Initial Treatment Phase
The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid Cancer
The psychosomatic symptoms of patients with differentiated thyroid cancer (DTC) during the initial treatment phase need to be improved.
- Conditions
- Pathologically Confirmed Differentiated Thyroid Carcinoma, All Patients Are in the Initial Treatment Phase, Normal Cognitive and Communicative Abilities, Capable of Reading and Understanding Questionnaires in Chinese, Ability to Use a Smartphone
- Trial name
- NCT06422702
- Testing
- Psychosomatic Symptoms Intervention, Extended supportive care
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Harbin Medical University
Thyroid Cancer, Papillary Thyroid Cancer
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
Now, the investigators carried out a prospective study enrolling patients with thyroid cancer, who had received ablative thyroidectomy and /or radioactive iodine therapy for two more years.
- Conditions
- Thyroid Cancer, Papillary Thyroid Cancer, Follicular Thyroid Cancer
- Trial name
- NCT04948437
- Where
- Taiwan
- Volunteers
- 103 people
- Sponsor
- National Taiwan University Hospital
Thyroid Cancer
Adjuvant Radiotherapy in High Risk Locally Advanced DTC
This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer.
- Trial name
- NCT06558981
- Testing
- Radiotherapy, radioiodine treatment
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Fudan University
Differentiated Thyroid Carcinoma (DTC)
Post-Marketing Surveillance of Lenvima in Korean Patients
The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.
- Trial name
- NCT02764554
- Where
- 32 sites in South Korea
- Volunteers
- 132 people
- Sponsor
- Eisai Korea Inc.
Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby…
- Conditions
- Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma, Locally Advanced Thyroid Gland Follicular Carcinoma, Locally Advanced Thyroid Gland Oncocytic Carcinoma
- Trial name
- NCT06959641
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Jochen Lorch
Differentiated Thyroid Cancer
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Locally advanced thyroid cancer has a wide range of surgery, large trauma and high local recurrence rate. It is one of the main causes of death in patients with thyroid cancer.
- Trial name
- NCT05989425
- Testing
- surufatinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Differentiated Thyroid Carcinoma (DTC), Neoadjuvant Therapy
Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma
This study is a single-arm, prospective investigation aimed at evaluating the efficacy of Sinibolimab combined with Lenvatinib as neoadjuvant therapy for locally advanced unresectable differentiated thyroid carcinoma in a Phase…
- Trial name
- NCT06848920
- Testing
- Immunotherapy combined with Multikinase inhibitors in neoadjuvant treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery.
- Conditions
- Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma
- Trial name
- NCT02973997
- Testing
- Laboratory Biomarker Analysis, Lenvatinib, Lenvatinib Mesylate
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Academic and Community Cancer Research United
Differentiated Thyroid Carcinoma, TCM Syndrome Type
Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer
The purpose of this study is to make a dialectical classification of patients who will receive 131I treatment after operation of thyroid cancer from the point of view of dialectics of syndrome elements of traditional Chinese…
- Trial name
- NCT04916262
- Volunteers
- 160 people
- Sponsor
- Qianfoshan Hospital
Differentiated Thyroid Cancer, Pediatric Cancer
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy.
- Conditions
- Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
- Trial name
- RAISE (NCT06458036)
- Testing
- Selpercatinib Monotherapy, 131I Therapy
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital of Philadelphia